Acrigen Biosciences

Executive Summary

Acrigen Biosciences is a private gene editing company headquartered in Philadelphia, focused on advancing CRISPR-based therapeutics for genetic diseases. Founded in 2018, the company has developed novel αCas and μCas CRISPR editors paired with engineered anti-CRISPR proteins (ErAcrs) to create a precision gene editing toolbox. This proprietary platform aims to achieve best-in-class efficiency and specificity, addressing key limitations of existing CRISPR technologies. Acrigen's approach holds promise for treating a wide range of genetic disorders by enabling safer and more accurate genome modifications. While still in early preclinical stages, Acrigen's innovative platform has potential to differentiate in the competitive gene editing landscape. The company is likely seeking partnerships and funding to advance its programs toward the clinic. If successful, Acrigen could establish a leading position in precision gene editing. However, significant technical, regulatory, and commercial hurdles remain. The near-term outlook depends on securing capital and demonstrating proof-of-concept in vivo data.

Upcoming Catalysts (preview)

• Q2 2026Preclinical Proof-of-Concept Data at Major Conference60% success
• H2 2026Series A Financing Round50% success
• 2027Strategic Partnership with Large Pharma30% success